Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 1/20 | 0.65 |
| ▸ | TUBB | P07437 | 1/20 | 0.65 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.65 |
| ▸ | AR | P10275 | 1/20 | 0.65 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.65 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.65 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.65 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.65 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.65 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.65 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.65 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.65 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.65 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.65 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.65 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4740487 | 0.89 | MEN1 (0.60) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL29491367 | 0.89 | HPGD (0.54) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL30175403 | 0.89 | MEN1 (0.60) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL4740488 | 0.89 | MEN1 (0.60) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL677432 | 0.88 | MAPT (0.62) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL8778476 | 0.88 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL8778480 | 0.88 | TUBB4A (0.52) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL4541307 | 0.88 | CYP19A1 (0.62) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL283216 | 0.85 | CYP19A1 (0.67) | TUBB4ATUBBTUBA3CARTUBA1B | |
| SCHEMBL11433075 | 0.84 | MEN1 (0.54) | TUBB4ATUBBTUBA3CARTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0253548-A2 | Method for the determination of occult blood and chemical compositions therefor | SAVYON DIAGNOSTICS LTD. (IL) | 1988-01-20 | — | — | EP | claimed |
| CN-103333071-A | 10-benzylideneanthrone compound and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2013-10-02 | — | — | CN | disclosed |
| CN-103333071-A | 10-benzylideneanthrone compound and application thereof | UNIV ZHEJIANG TECHNOLOGY | 2013-10-02 | — | — | CN | disclosed |
| US-8318726-B2 | Benzylidineanthracenone linked pyrrolobenzodiazepine hybrids useful as anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-11-27 | — | — | US | disclosed |
| US-8318726-B2 | Benzylidineanthracenone linked pyrrolobenzodiazepine hybrids useful as anticancer agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2012-11-27 | — | — | US | disclosed |
| US-20120142913-A1 | BENZYLIDINEANTHRACENONE LINKED PYRROLOBENZODIAZEPINE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2012-06-07 | — | — | US | disclosed |
| US-20120142913-A1 | BENZYLIDINEANTHRACENONE LINKED PYRROLOBENZODIAZEPINE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2012-06-07 | — | — | US | disclosed |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | AETERNA ZENTARIS GMBH (DE) | 2008-02-28 | — | — | US | disclosed |
| WO-2008015265-A1 | ANTHRACEN DERIVATIVES AND THEIR USE FOR THE TREATMENT OF BENIGN AND MALIGNANT TUMOROUS DISEASES | ÆTERNA ZENTARIS GMBH (DE) | 2008-02-07 | — | — | WO | disclosed |
| EP-0253548-A2 | Method for the determination of occult blood and chemical compositions therefor | SAVYON DIAGNOSTICS LTD. (IL) | 1988-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142913-A1 | BENZYLIDINEANTHRACENONE LINKED PYRROLOBENZODIAZEPINE HYBRIDS USEFUL AS ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | GABRA5, CYP3A5, CYP1B1 | TUBB4A 624/4885TUBB 726/4885TUBA3C 541/4885 |
| US-20080051463-A1 | ANTHRACENE COMPOUNDS AND THEIR USE FOR TREATING BENIGN AND MALIGNANT TUMOR DISORDERS | TUBB1, TUBA1C, TUBB3 | TUBB4A 11/4885TUBB 5/4885TUBA3C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.